<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017197</url>
  </required_header>
  <id_info>
    <org_study_id>RCT 01 GW</org_study_id>
    <secondary_id>U1111-1155-4833</secondary_id>
    <nct_id>NCT02017197</nct_id>
  </id_info>
  <brief_title>Therapeutic Equivalence Between Branded and Generic Warfarin Tablets in Brazil</brief_title>
  <official_title>Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the switch from branded to generic warfarin
      or between different generic warfarin tablets may cause fluctuation in the results of
      coagulation tests (International Normalized Rate, acronym INR) in patients, thus
      predisposing them to unnecessary risks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Objective

           1.1 Main Objective

           We aim to determine, through mean INR change from baseline results, whether there is
           therapeutic equivalency between the branded warfarin sodium (Marevan®) and the generic
           formulations in atrial fibrillation patients in Brazil.

           1.2 Specific Objective

           In order to achieve the objective, we aim to assess with each warfarin formulation:

             -  mean INR;

             -  mean prothrombin time (PT);

             -  the incidence of thromboembolic events;

             -  the incidence of bleeding;

             -  the time in therapeutic range;

             -  and compliance with treatment.

        2. Hypothesis

           Our hypothesis is that the mean INR of patients when using the generic tablets of
           warfarin sodium does not differ by more than 0.49 (two-sided) from the mean INR
           obtained when using the branded formulation, thereby demonstrating therapeutic
           equivalence.

        3. Type of Study

           This study is a crossover randomized controlled equivalence trial. It comprises four
           phases, being the first one a three-week long run-in period and the following phases
           each four-week long. Patients will use a different warfarin sodium tablet formulation
           in each one of the phases 2, 3 and 4: either the branded Marevan® (União
           Química/Farmoquímica, Brasil), or two generic drugs, (manufactured by União Química
           Farmacêutica Nacional S/A or Laboratório Teuto Brasileiro S/A, Brasil) purchased from
           Brazilian drugstores (not directly from the manufacturer). Every patient will use each
           one of the three formulations in a previously determined sequence (A, B, C, D, E or F)
           to which he was assigned by randomization.

           Since patients included in the study will already be using warfarin and it is not
           ethically acceptable to interrupt this treatment, we planned a run-in period equivalent
           to seven warfarin half-lives, long enough to washout any previous warfarin treatment.
           Then, in this first phase, patients will start treatment with the same warfarin
           formulation that will be used in the second phase thus avoiding the carry-over effect.
           Also, data derived from this first phase will not be considered in the final analysis.
           This period will also be used to select patients compliant with treatment, accepting
           those with at least 70% TTR.

        4. Methods

           An independent investigator (initials TFCP) will use a computer random number generator
           to allocate patients to one of the six sequences of treatment. The principal
           investigator (initials CGF) will separate, repack and dispense drugs for patients in
           opaque drug containers of identical appearance. This process will be based on the
           initials of the patient and the alphanumeric code, maintaining the allocation
           concealment since TFCP will be responsible for assigning to the repacked drugs the
           patient initials and the alphanumeric code correlated with the formulation of warfarin
           utilized. TFCP will also be accountable to conceal the allocation until the statistical
           analysis at the end of the study. Due to the features of the drug containers,
           physicians and the principal investigator (that assess patients and collect outcomes)
           will be blinded. Patients may not be blinded depending on the appearance of the
           manufactured tablets, but the main outcome will be a laboratory result (INR).

        5. Sample Size

           Forty-eight patients (eight in each group) is the minimum necessary number of
           individuals to detect a clinically significant fluctuation of 0.49 in the mean INR,
           with a 90% power at a 5% level of significance, if one were present. This sample size
           was estimated considering the Pocock's statistical method for quantitative outcomes and
           an achieved mean INR and standard deviation with the branded warfarin of 2.45 and 0.29
           respectively. To compensate possible withdrawals or exclusions of patients we plan to
           recruit 60 patients (ten in each group).

        6. Statistical Analysis

           For the INR and PT outcomes paired t-test will be used at a two-sided 5% level of
           significance. These analysis will be per protocol, i.e., data from patients that during
           the follow-up start treatment with substances or drugs that interact either in a
           moderate or major way or are contraindicated when used with warfarin (Annex I) will be
           excluded.

           Binary outcomes (TTR, thromboembolic or bleeding events) will be analysed by Mcnemar
           test at a 5% level of significance using intention to treat i.e. considering missing
           data as adverse outcomes. In this case sensibility analysis will be conducted.
           Exploratory analysis for subgroup of patients are not intended.

        7. Annex I (obtained from the online database Micromedex ® 2.0 in September 13, 2013)

             -  abciximab

             -  acarbose

             -  acemetacin

             -  acenocoumarol

             -  acetaminophen

             -  agrimony

             -  alclofenac

             -  alefacept

             -  allopurinol

             -  aloe

             -  aminoglutethimide

             -  amiodarone

             -  amitriptyline

             -  amobarbital sodium

             -  amoxapine

             -  amoxicillin

             -  ampicillin trihydrate

             -  amprenavir

             -  angelica

             -  anise

             -  antithyroid agents

             -  apazone

             -  apixaban

             -  aprepitant

             -  aprobarbital

             -  argatroban

             -  armodafinil

             -  arnica

             -  asafetida

             -  aspirin

             -  astragalus

             -  atazanavir

             -  atenolol

             -  atovaquone

             -  avocado

             -  azathioprine

             -  azithromycin

             -  bee pollen

             -  benoxaprofen

             -  benzbromarone

             -  betamethasone

             -  bicalutamide

             -  bilberry

             -  bismuth subsalicylate

             -  bivalirudin

             -  black cohosh extract

             -  black currant

             -  black haw

             -  black tea

             -  bladderwrack

             -  boceprevir

             -  bogbean

             -  boldo

             -  borage

             -  bosentan

             -  bromelain

             -  bromfenac

             -  buchu

             -  bufexamac

             -  butabarbital

             -  butalbital

             -  capecitabine

             -  capsaicin

             -  carbamazepine

             -  carbenicillin disodium

             -  carboplatin

             -  carprofen

             -  cassia

             -  cat's claw

             -  cefadroxil

             -  cefamandole

             -  cefazolin sodium

             -  cefdinir

             -  cefepime

             -  cefixime

             -  cefoperazone

             -  cefotaxime

             -  cefotetan

             -  cefpodoxime

             -  ceftazidime

             -  ceftibuten

             -  ceftizoxime

             -  ceftriaxone

             -  celecoxib

             -  celery

             -  cephalexin

             -  cephalothin sodium

             -  cephapirin

             -  chamomile

             -  chaparral

             -  chitosan

             -  chloral hydrate

             -  chloramphenicol

             -  chlordiazepoxide

             -  chlorotrianisene

             -  chlorpromazine hydrochloride

             -  cholestyramine

             -  chondroitin

             -  cimetidine

             -  cinchona

             -  ciprofloxacin

             -  cisapride monohydrate

             -  cisplatin

             -  citalopram

             -  clarithromycin

             -  clofibrate

             -  clomipramine hydrochloride

             -  clopidogrel

             -  clove

             -  clove oil

             -  cloxacillin benzathine

             -  coenzyme Q10

             -  colesevelam

             -  contraceptives, combination

             -  cortisone

             -  cranberry juice

             -  curcumin

             -  cyclophosphamide

             -  cyclosporine, modified

             -  dabigatran

             -  dabrafenib

             -  dalteparin

             -  danaparoid

             -  danazol

             -  dandelion

             -  dapsone

             -  darunavir

             -  deferasirox

             -  delavirdine

             -  demeclocycline

             -  desipramine

             -  desvenlafaxine

             -  devil's claw

             -  dexamethasone

             -  dexlansoprazole

             -  dexmethylphenidate

             -  diazoxide

             -  diclofenac

             -  dicloxacillin

             -  diethylstilbestrol

             -  diflunisal

             -  dipyridamole

             -  dipyrone

             -  disopyramide

             -  disulfiram

             -  dong quai

             -  dothiepin

             -  doxepin

             -  doxorubicin

             -  doxycycline calcium

             -  dronedarone

             -  droxicam

             -  duloxetine

             -  enoxacin

             -  enoxaparin

             -  enteral nutrition

             -  enzalutamide

             -  eptifibatide

             -  erlotinib

             -  erythromycin acistrate

             -  escitalopram

             -  esomeprazole

             -  eterobarb

             -  ethacrynic acid

             -  ethanol

             -  ethchlorvynol

             -  ethotoin

             -  etodolac

             -  etoposide

             -  etravirine

             -  etretinate

             -  evening primrose oil

             -  exenatide

             -  ezetimibe

             -  felbamate

             -  fenbufen

             -  fenofibrate

             -  fenofibric acid

             -  fenoprofen

             -  fenugreek

             -  feverfew

             -  fish oil

             -  floctafenine

             -  flosequinan

             -  fluconazole

             -  fludrocortisone acetate

             -  flufenamic acid

             -  fluorouracil

             -  fluoxetine

             -  fluoxymesterone

             -  flurbiprofen

             -  flutamide

             -  fluvastatin

             -  fluvoxamine

             -  fosamprenavir

             -  fosaprepitant

             -  garlic

             -  gatifloxacin

             -  gefitinib

             -  gemcitabine

             -  gemfibrozil

             -  gemifloxacin

             -  ginger

             -  ginkgo

             -  ginseng, siberian

             -  glimepiride

             -  glipizide

             -  glucagon

             -  glucosamine

             -  glutethimide

             -  glyburide

             -  goldenseal

             -  green tea

             -  griseofulvin

             -  guggul

             -  halothane

             -  heparin calcium

             -  heptabarbital

             -  hexobarbital sodium

             -  high protein food

             -  horse chestnut

             -  horseradish

             -  hydrocortisone

             -  ibritumomab

             -  ibuprofen

             -  ifosfamide

             -  imatinib

             -  imipramine hydrochloride

             -  indomethacin

             -  indoprofen

             -  infliximab

             -  influenza virus vaccine

             -  ipriflavone

             -  isoniazid

             -  isoxicam

             -  itraconazole

             -  ivacaftor

             -  ivermectin

             -  kava

             -  ketoconazole

             -  ketoprofen

             -  ketorolac tromethamine

             -  lactulose

             -  lansoprazole

             -  leflunomide

             -  lepirudin

             -  levamisole

             -  levofloxacin

             -  licorice

             -  lopinavir

             -  lornoxicam

             -  lovastatin

             -  lycium

             -  marijuana

             -  meadowsweet

             -  mechlorethamine

             -  meclofenamate

             -  mefenamic acid

             -  melatonin

             -  meloxicam

             -  menthol

             -  mephobarbital

             -  mercaptopurine

             -  mesalamine

             -  mesna

             -  methandrostenolone

             -  methicillin

             -  methotrexate

             -  methyl salicylate

             -  methylphenidate

             -  methylprednisolone acetate

             -  methyltestosterone

             -  metronidazole

             -  miconazole

             -  mifepristone

             -  milnacipran

             -  minocycline hydrochloride

             -  mistletoe

             -  mitotane

             -  moricizine hydrochloride

             -  motherwort

             -  moxalactam

             -  moxifloxacin

             -  nabumetone

             -  nafcillin

             -  nalidixic acid

             -  nandrolone

             -  naproxen

             -  nelfinavir

             -  neomycin

             -  nettle extract

             -  nevirapine

             -  niacin

             -  nilutamide

             -  nimesulide

             -  norfloxacin

             -  nortriptyline hydrochloride

             -  noscapine

             -  ofloxacin

             -  omega-3-acid ethyl esters

             -  omeprazole

             -  onion oil

             -  orlistat

             -  oseltamivir

             -  oxacillin

             -  oxandrolone

             -  oxaprozin

             -  oxymetholone

             -  oxyphenbutazone

             -  oxytetracycline

             -  pantoprazole

             -  papaya

             -  paramethasone

             -  paroxetine

             -  parsley

             -  passionflower

             -  pau d'arco

             -  penicillin G

             -  penicillin V benzathine

             -  pentosan polysulfate sodium

             -  pentoxifylline

             -  phenindione

             -  phenobarbital

             -  phenprocoumon

             -  phenylbutazone

             -  phenytoin

             -  phytonadione

             -  piperacillin

             -  piracetam

             -  pirazolac

             -  piroxicam

             -  pirprofen

             -  policosanol

             -  pomegranate

             -  poplar

             -  posaconazole

             -  prasugrel

             -  prednisolone

             -  prednisone

             -  prickly ash

             -  primidone

             -  procarbazine

             -  proguanil

             -  propafenone hydrochloride

             -  propoxyphene

             -  propranolol

             -  propyphenazone

             -  proquazone

             -  protriptyline

             -  pumpkin seed

             -  quassia

             -  quetiapine

             -  quinestrol

             -  quinidine

             -  quinine

             -  rabeprazole sodium

             -  raloxifene

             -  ranitidine

             -  red clover

             -  rifabutin

             -  rifampin

             -  rifapentine

             -  rifaximin

             -  rilonacept

             -  ritonavir

             -  rivaroxaban

             -  rofecoxib

             -  romidepsin

             -  ropinirole

             -  rosuvastatin

             -  roxithromycin

             -  salicylates

             -  saquinavir

             -  sarsaparilla

             -  saw palmetto extract

             -  secobarbital

             -  senega

             -  sertraline

             -  simvastatin

             -  sitaxsentan

             -  skullcap

             -  sorafenib

             -  soybean

             -  spironolactone

             -  st john's wort

             -  stanozolol

             -  sucralfate

             -  sulfamethoxazole

             -  sulfasalazine

             -  sulfinpyrazone

             -  sulfisoxazole

             -  sulindac

             -  sulofenur

             -  suprofen

             -  sweet woodruff

             -  tamarind

             -  tamoxifen

             -  tan shen

             -  teduglutide

             -  telaprevir

             -  telithromycin

             -  tenidap sodium

             -  tenoxicam

             -  terbinafine

             -  teriflunomide

             -  testosterone

             -  tetracycline

             -  thyroid hormones

             -  tiaprofenic acid

             -  tibolone

             -  ticarcillin

             -  ticlopidine

             -  tigecycline

             -  tinidazole

             -  tinzaparin

             -  tirofiban

             -  tocilizumab

             -  tolmetin

             -  tolterodine tartrate

             -  tonka

             -  toremifene citrate

             -  torsemide

             -  tramadol

             -  trastuzumab

             -  treprostinil

             -  triamcinolone acetonide

             -  trimipramine

             -  valdecoxib

             -  valproic acid

             -  vancomycin

             -  vemurafenib

             -  venlafaxine

             -  vilazodone

             -  vincristine

             -  vindesine

             -  vitamin A

             -  vitamin E

             -  vitamin K

             -  voriconazole

             -  vorinostat

             -  wild lettuce

             -  willow

             -  wintergreen

             -  yarrow

             -  zafirlukast

             -  zileuton

             -  zomepirac sodium

             -  zotepine
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change in INR with each generic formulation</measure>
    <time_frame>After four weeks with each formulation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>INR: International normalized ratio. The final analysis will not consider data from the run-in period (phase 1). INR will be assessed twice a month during the 15 weeks of study.
Mean INR for each patient will be measured while using each generic formulation of warfarin; the baseline will be the mean INR during the use of the branded warfarin (Marevan®). Outcome will then be the mean difference between these two measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in PT with each generic formulation</measure>
    <time_frame>After four weeks with each formulation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PT: prothrombin time. The final analysis will not consider data from the run-in period (phase 1). PT will be assessed twice a month during the 15 weeks of study.
Mean PT for each patient will be measured while using each generic formulation of warfarin; the baseline will be the mean PT during the use of the branded warfarin (Marevan®). Outcome will then be the mean difference between these two measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic events</measure>
    <time_frame>At weeks 7, 11 and 15 (i.e. at the end of phases 2, 3 and 4)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Includes ischemic stroke (differential diagnosis with hemorrhagic stroke by tomography) and thromboembolism of viscera or extremities (diagnosed by acute symptoms and relevant diagnostic tests). The final analysis will not consider data from the run-in period (phase 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in therapeutic range (TTR)</measure>
    <time_frame>At weeks 7, 11 and 15 (i.e. at the end of phases 2, 3 and 4)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>TTR calculated by Rosendaal Method also known as linear interpolation method. The final analysis will not consider data from the run-in period (phase 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding events</measure>
    <time_frame>At weeks 7, 11 and 15 (i.e. at the end of phases 2, 3 and 4)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Classified as major or minor bleeding events.
Major: intracranial hemorrhage, fatal bleeding, bleeding resulting in hemoglobin  loss equal to or greater than 2.0 g / L, hemorrhage requiring transfusion, bleeding in sensitive areas such as the retina or pericardium.
Minor: all other bleeding.
The final analysis will not consider data from the run-in period (phase 1).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance with treatment</measure>
    <time_frame>Monthly (from the beginning of treatment up to week 15).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Performed by counting of returned pills</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 (3-week run-in period): Marevan®
Phase 2 (4 weeks): Marevan®
Phase 3 (4 weeks): generic warfarin #1
Phase 4 (4 weeks): generic warfarin #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 (3-week run-in period): generic warfarin #1
Phase 2 (4 weeks): generic warfarin #1
Phase 3 (4 weeks): Marevan®
Phase 4 (4 weeks): generic warfarin #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 (3-week run-in period): generic warfarin #1
Phase 2 (4 weeks): generic warfarin #1
Phase 3 (4 weeks): generic warfarin #2
Phase 4 (4 weeks): Marevan®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 (3-week run-in period): Marevan®
Phase 2 (4 weeks): Marevan®
Phase 3 (4 weeks): generic warfarin #2
Phase 4 (4 weeks): generic warfarin #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 (3-week run-in period): generic warfarin #2
Phase 2 (4 weeks): generic warfarin #2
Phase 3 (4 weeks): Marevan®
Phase 4 (4 weeks): generic warfarin #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 (3-week run-in period): generic warfarin #2
Phase 2 (4 weeks): generic warfarin #2
Phase 3 (4 weeks): generic warfarin #1
Phase 4 (4 weeks): Marevan®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marevan®</intervention_name>
    <description>Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <other_name>warfarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic warfarin #1</intervention_name>
    <description>Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic warfarin #2</intervention_name>
    <description>Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of nonvalvular atrial fibrillation by electrocardiogram and
             echocardiography;

          -  CHA2DS2VASc score equal to or greater than 1;

          -  already in use of warfarin;

          -  signing of Informed Consent Form.

        Exclusion Criteria:

          -  patients with contraindications to the use of anticoagulants (patients either  taking
             other anticoagulants, or with active bleeding, or hypersensitive to warfarin or with
             ulcers);

          -  women of childbearing age, pregnant or breastfeeding;

          -  patients with thrombocytopenia;

          -  patients with hepatic or renal impairment;

          -  patients with a history of bleeding episodes due to congenital deficiency of
             coagulation factors;

          -  patients enrolled in another trial;

          -  patients not achieving at least 70% TTR in the run-in period

          -  patients initiating treatment with drugs with either moderate or major interactions
             or which are contraindicated when used concomitantly with warfarin, according to our
             list (Annex I).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Gomes Freitas, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Sao Paulo (UNIFESP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina Gomes Freitas, PharmD</last_name>
    <phone>+551155764203</phone>
    <email>carolina.freitas@unifesp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital São Paulo/Hospital Universitário da UNIFESP (University Hospital of UNIFESP)</name>
      <address>
        <city>São Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Gomes Freitas, BPharm</last_name>
      <phone>+551155752970</phone>
      <email>carolina.freitas@unifesp.br</email>
    </contact>
    <investigator>
      <last_name>Carolina Gomes Freitas, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 24, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Carolina Gomes Freitas</investigator_full_name>
    <investigator_title>Graduate student (masters)</investigator_title>
  </responsible_party>
  <keyword>Therapeutic Equivalency</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Drugs, Generic</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>Anticoagulants [Pharmacological Action]</keyword>
  <keyword>Coumarins</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
